Brandes Investment Partners 13F: Adds $114M to ICLR Stake

Brandes Investment Partners Expands ICON plc Position

Brandes Investment Partners grew its stake in ICON Public Limited Company (NasdaqGS: ICLR) by 84.8% during the period ended May 15, 2026, according to a Form 13F filing with the Securities and Exchange Commission. The firm added 658,321 shares to bring its holdings to 1,435,053 shares. The reported value of the investment reached approximately $249.3 million based on the underlying period data.

ICON plc Shares Trade Near Recent Levels

ICON shares changed hands around $173.71 recently, tracking well above the 52-week low of $66.57 while remaining below the 52-week high of $203.91. The company has a market capitalization of roughly $13.08 billion. Its forward P/E ratio sits at 14.4, reflecting how investors price upcoming earnings relative to the broader diagnostics and research sector.

Wall Street Analysts Adjust Price Targets

Several research firms have updated their views on the clinical research provider. On June 25, 2026, BMO Capital maintained an outperform rating with a $187.00 price target, up from its prior $160.00 mark. On the same day, Barclays maintained an equal-weight rating while raising its target to $175.00 from $160.00. Mizuho kept an outperform rating with a $190.00 target on June 26, 2026. Shortly after, Truist Securities upgraded the stock to a buy rating with a $207.00 target on June 30, 2026, later lifting that target to $209.00 on July 31, 2026. Citigroup maintained a neutral rating while adjusting its target across multiple dates, moving from $140.00 on June 25, 2026, to $180.00 on July 31, 2026, and later settling at $175.00 on September 18, 2026. Overall, the stock carries a consensus buy recommendation from 16 analysts with a mean target price of $185.25.

Clinical Research Operations in Dublin

Headquartered in Dublin, Ireland, ICON Public Limited Company provides outsourced development and commercialization services for pharmaceutical, biotechnology, and medical device clients. The firm manages clinical trials from early phase development to post-approval studies. Institutional interest from managers like Brandes underscores ongoing portfolio allocations toward healthcare service providers.

What to Watch at ICON Public Limited Company

Investors will look toward the company's next earnings report scheduled for October 21, 2026, to gauge ongoing demand across global clinical trials. Because 13F filings look backward at holdings from past periods, these disclosures reflect past portfolio adjustments rather than live trading activity.